Mesoblast (MESO) EBITDA Margin (2014 - 2023)
Mesoblast (MESO) posted EBITDA Margin of 943.77% for Q2 2023, down 514.91% sequentially from 153.48% in Q1 2023, and down 94814.0% YoY from N/an in Q2 2022.
Mesoblast (MESO) EBITDA Margin (2014 - 2023) Analysis & Trends
Mesoblast has reported EBITDA Margin for 10 years, with the latest figure at 943.77% in Q2 2023.
- Quarterly EBITDA Margin fell 94814.0% year-over-year to 943.77% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 573.74% (down 309.0% YoY) and the FY2025 annual result came in at 360.79%, up 63538.0% from the prior year.
- EBITDA Margin fell to 943.77% in Q2 2023 per MESO's latest filing, from 153.48% in the prior quarter.
- Over five years, EBITDA Margin peaked at 4.37% in Q2 2022 and troughed at 2306.24% in Q1 2019.
- A 5-year average of 823.91% and a median of 827.37% in 2021 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2019 and 2020: EBITDA Margin soared 188278 bps in 2019, then slumped 143079 bps in 2020.
- Over 5 years, EBITDA Margin stood at 1180.85% in 2019, then grew by 18 bps to 964.93% in 2020, then grew by 8 bps to 888.15% in 2021, then climbed by 27 bps to 650.05% in 2022, then sank by 45 bps to 943.77% in 2023.
- According to Business Quant data, EBITDA Margin over the past three periods registered 943.77%, 153.48%, and 650.05% for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -943.77% |
| Mar 31, 2023 | -153.48% |
| Dec 31, 2022 | -650.05% |
| Sep 30, 2022 | -558.27% |
| Jun 30, 2022 | 4.37% |
| Mar 31, 2022 | -417.50% |
| Dec 31, 2021 | -888.15% |
| Sep 30, 2021 | -766.60% |
| Jun 30, 2021 | -904.66% |
| Mar 31, 2021 | -1,157.46% |
| Dec 31, 2020 | -964.93% |
| Sep 30, 2020 | -1,635.86% |
| Jun 30, 2020 | -64.75% |
| Mar 31, 2020 | -648.01% |
| Dec 31, 2019 | -1,180.85% |
| Sep 30, 2019 | -205.07% |
| Jun 30, 2019 | -1,389.17% |
| Mar 31, 2019 | -2,306.24% |
| Dec 31, 2018 | -2,461.38% |
| Sep 30, 2018 | -2,087.85% |